Lupin says FDA raises concerns over Pithampur plant | Mint
Active Stocks
Mon Feb 26 2024 15:59:59
  1. Tata Steel share price
  2. 142.60 -1.99%
  1. Power Grid Corporation Of India share price
  2. 287.75 1.97%
  1. HDFC Bank share price
  2. 1,422.25 0.10%
  1. ITC share price
  2. 409.20 -0.58%
  1. State Bank Of India share price
  2. 759.00 -0.05%
Business News/ Companies / Lupin says FDA raises concerns over Pithampur plant
BackBack

Lupin says FDA raises concerns over Pithampur plant

The FDA issued the company a so-called Form 483, listing six observations on the manufacturing processes

The FDA had audited two of Lupin’s facilities—the Lupin Bioresearch Center in Pune and its manufacturing facility at Pithampur near Indore. Photo: Ramesh Pathania/MintPremium
The FDA had audited two of Lupin’s facilities—the Lupin Bioresearch Center in Pune and its manufacturing facility at Pithampur near Indore. Photo: Ramesh Pathania/Mint

New Delhi: The US Food and Drug Administration (FDA) raised concerns over production processes at drugmaker Lupin Ltd’s Pithampur facility following an inspection in January, the company said on Monday.

The FDA had audited two of Lupin’s facilities—the Lupin Bioresearch Center, Pune (LBC) and its manufacturing facility at Pithampur near Indore—in November 2014 and then in January 2015.

After the Pithampur audit, the FDA issued the company a so-called Form 483, listing six observations on the manufacturing processes at the plant, a statement issued by the drugmaker said.

In a Form 483, the FDA typically outlines conditions or practices at a drug-making unit that may cause the products made there to be in violation of the US agency’s standard production requirements.

The Lupin stock ended 2.71% down at 1,645.10 on the BSE on Monday, while the BSE healthcare index fell 0.83% to 977.35 points and the benchmark Sensex fell 0.88% to close at 28,975.11 points.

Industry experts maintain a neutral rating on the company’s stock.

“Both audits were completed successfully with the Pune facility not receiving any observations and the Indore facility receiving six observations (483s). Since then, the Indore facility has received one ANDA approval and two site-transfer approvals. While currently, the details of the observations are not known, (though should not be serious given that the company has got approvals after the observation), hence we are not changing our estimates, though the material impact of the damage should not be high," said Sarabjit Kour Nangra, vice-president, (research - pharma) at Angel Broking Ltd.

ANDA is short for abbreviated new drug application.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 23 Feb 2015, 04:15 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App